Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Accuray Incorporated is a medical devices business based in the US. Accuray Incorporated shares (ARAY) are listed on the NASDAQ and all prices are listed in US Dollars. Accuray Incorporated employs 932 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$1.68 - $6.02|
|50-day moving average||$5.12|
|200-day moving average||$4.40|
|Wall St. target price||$8.20|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.08|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Accuray Incorporated stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Accuray Incorporated's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Accuray Incorporated's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 66x. In other words, Accuray Incorporated shares trade at around 66x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Accuray Incorporated's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.08. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Accuray Incorporated's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Accuray Incorporated's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $34 million.
The EBITDA is a measure of a Accuray Incorporated's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$377.3 million|
|Operating margin TTM||7.12%|
|Gross profit TTM||$149.7 million|
|Return on assets TTM||3.51%|
|Return on equity TTM||11.43%|
|Market capitalisation||$492.2 million|
TTM: trailing 12 months
There are currently 6.4 million Accuray Incorporated shares held short by investors – that's known as Accuray Incorporated's "short interest". This figure is 7.8% down from 6.9 million last month.
There are a few different ways that this level of interest in shorting Accuray Incorporated shares can be evaluated.
Accuray Incorporated's "short interest ratio" (SIR) is the quantity of Accuray Incorporated shares currently shorted divided by the average quantity of Accuray Incorporated shares traded daily (recently around 708197.43589744). Accuray Incorporated's SIR currently stands at 8.97. In other words for every 100,000 Accuray Incorporated shares traded daily on the market, roughly 8970 shares are currently held short.
However Accuray Incorporated's short interest can also be evaluated against the total number of Accuray Incorporated shares, or, against the total number of tradable Accuray Incorporated shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Accuray Incorporated's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Accuray Incorporated shares in existence, roughly 70 shares are currently held short) or 0.0696% of the tradable shares (for every 100,000 tradable Accuray Incorporated shares, roughly 70 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Accuray Incorporated.
Find out more about how you can short Accuray Incorporated stock.
We're not expecting Accuray Incorporated to pay a dividend over the next 12 months.
Over the last 12 months, Accuray Incorporated's shares have ranged in value from as little as $1.68 up to $6.02. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Accuray Incorporated's is 1.9355. This would suggest that Accuray Incorporated's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa, and rest of the Asia Pacific region. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. The company also offers the TomoTherapy System, including the Radixact System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. It markets its products in the United States directly, as well as through sales organizations, sales agents, and group purchasing organizations; and directly, as well as through distributors and sales agents in Europe, Asia, and South America to hospitals and stand-alone treatment facilities. The company was incorporated in 1990 and is headquartered in Sunnyvale, California. .
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZIONL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.